Double digit increases in drug spending on new “specialty” drugs is noted here.
In the article it is noted that “Spending on cancer drugs known as antineoplastics, which were administered outside a doctor’s office, rose 19.2 percent, the third largest jump. The price per prescription rose by almost 15 percent to nearly $1,600 on average, making inflation the primary driver of the spending increase.”
I hadn’t noticed inflation at over 15% in other sectors.Â Remember, the fiduciary responsibility of drug industry executives is not providing quality health care, rather it is to maximize profits. This needs to change!